Toxicol Res.
2013 Sep;29(3):217-219.
Mutagenic Assessment of Olmesartan Cilexetil by Bacterial Mutation Assay
- Affiliations
-
- 1Department of Pharmacology, CKD Research Institute, Yongin, Korea.
- 2Toxicological Screening and Testing Division, National Institute of Food and Drug Safety Evaluation, Osong, Korea.
- 3College of Pharmacy, Dankook University, Cheonan, Korea. kyubong@dankook.ac.kr
- 4CTC BIO Inc. Paltan, Hwaseong, Korea.
Abstract
- Hypertension is a serious health problem due to high frequency and concomitant other diseases including cardiovascular and renal dysfunction. Olmesartan cilexetil is a new antihypertensive drug associated with angiotensin II receptor antagonist. This study was conducted to evaluate the mutagenicity of olmesartan cilexetil by bacterial reverse mutation test using Salmonella typhimurium (TA100, TA1535, TA98, and TA1537) and Escherichia coli (WP2 uvrA). At the concentrations of 0, 62, 185, 556, 1667, and 5000 microg/plate, olmesartan cilexetil was negative in both Salmonella typhimurium and Escherichia coli regardless of presence or absence of metabolic activation system (S9 mix). These results demonstrate that olmesartan cilexetil does not induce bacterial reverse mutation.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Determination of candesartan or olmesartan in hypertensive patient plasma using UPLC-MS/MS
- Olmesartan-associated Enteropathy with Acute Kidney Injury
- A Clinical Study on Anti-Hypertensive Effect and Safety of Candesartan Cilexetil (Atacand) in Mild to Moderate Hypertensive Patients
- Genotoxicity Assessment of Erythritol by Using Short-term Assay
- Correlation-based and feature-driven mutation signature analyses to identify genetic features associated with DNA mutagenic processes in cancer genomes
